11 hours agoAnavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023
Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 2, 2022Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 8, 2022Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 3, 2022Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022
May 10, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results
May 3, 2022Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022
Feb 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 First Quarter Financial Results
Feb 3, 2022Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, 2/9/2022
Nov 17, 2021Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wed., November 24, 2021
